Alpha Lipoic Acid and Fatty Liver: Evidence

Alpha lipoic acid and fatty liver disease are increasingly discussed together as interest grows in antioxidant-based approaches to liver health. Fatty liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD, previously NAFLD), affects a significant proportion of the UK population, often without causing obvious symptoms. Alpha lipoic acid (ALA) is a naturally occurring compound with antioxidant and anti-inflammatory properties that may target some of the mechanisms driving liver cell damage. This article explores how ALA works, what the current evidence shows, and what people with liver problems should know before considering supplementation.

What is fatty liver disease and why does it develop?

Fatty liver disease occurs when excess fat accumulates in liver cells, driven by insulin resistance, obesity, type 2 diabetes, and poor diet. It can progress to steatohepatitis, fibrosis, and cirrhosis if left unmanaged.

Fatty liver disease occurs when excess fat accumulates within liver cells, impairing normal liver function over time. The condition is broadly divided into two main types: alcohol-related fatty liver disease (ARLD), caused by heavy or prolonged alcohol use, and metabolic dysfunction-associated steatotic liver disease (MASLD), which was previously known as non-alcoholic fatty liver disease (NAFLD). NICE guidance NG49 uses the term NAFLD, and the MASLD terminology reflects a more recent international nomenclature consensus (BASL/EASL 2023); both terms refer to the same underlying condition and may be used interchangeably in UK clinical settings.^[1]

The condition develops when the liver's capacity to process and export fat is overwhelmed. Key contributing factors include:

• Insulin resistance, which drives excess fatty acid delivery to the liver

• Obesity, particularly central or abdominal adiposity

• Type 2 diabetes and metabolic syndrome

• Poor dietary patterns, including high intake of refined carbohydrates and saturated fats

• Physical inactivity

In many people, fatty liver remains in a simple, non-progressive stage. However, in a proportion of individuals, ongoing inflammation leads to metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), which can progress to fibrosis, cirrhosis, and in some cases liver failure or hepatocellular carcinoma.^[3] The British Liver Trust estimates that fatty liver disease is common in the UK, with many cases remaining undiagnosed.

In UK primary care, initial assessment typically involves liver function tests and an ultrasound scan. GPs may also calculate a FIB-4 score (which uses age, liver enzyme levels, and platelet count) to assess the risk of significant fibrosis.^[1][4] Where indicated, an enhanced liver fibrosis (ELF) test may be arranged, and referral to hepatology is considered based on risk stratification thresholds set out in NICE NG49.^[1]

Oxidative stress, where an imbalance between harmful free radicals and the body's antioxidant defences damages liver cells, is considered a central mechanism in disease progression. This is particularly relevant when considering the potential role of antioxidant compounds such as alpha lipoic acid in supporting liver health.

How might alpha lipoic acid help with fatty liver?

ALA may help by reducing oxidative stress, improving insulin sensitivity, modulating inflammation, and activating AMPK to promote fat breakdown in the liver. These mechanisms are largely established in laboratory and animal studies.

Alpha lipoic acid (ALA) may help with fatty liver primarily through its antioxidant and anti-inflammatory properties, which target several of the mechanisms that drive liver cell damage. ALA is a naturally occurring compound synthesised in small amounts by the body and found in foods such as spinach, broccoli, and red meat. It is also available as a dietary supplement. It is not a licensed medicine in the UK, and the strengths commonly marketed in supplements typically range from 100 mg to 600 mg; these figures reflect what is available on the market rather than a recommended dose, and individuals should follow the product label and seek professional advice before use, particularly if they have any health conditions or take other medicines.

ALA is both water-soluble and fat-soluble, allowing it to act within a wide range of cellular environments.^[5] Its proposed mechanisms relevant to fatty liver include:

• Reducing oxidative stress by scavenging free radicals and regenerating other antioxidants, including vitamins C and E and glutathione^[5]

• Improving insulin sensitivity, which may reduce the delivery of excess fatty acids to the liver

• Modulating inflammatory pathways, potentially lowering levels of pro-inflammatory cytokines that contribute to liver cell injury

• Supporting mitochondrial function, which is often impaired in MASLD/NAFLD and contributes to fat accumulation and cellular damage

ALA also appears to influence lipid metabolism by activating AMP-activated protein kinase (AMPK), an enzyme that plays a key role in regulating energy balance and fat oxidation within the liver. By promoting fat breakdown and reducing fat synthesis, ALA may theoretically help reduce hepatic steatosis.

It is important to note that these mechanisms have been identified largely through laboratory and animal studies. The extent to which they translate meaningfully to clinical benefit in humans with fatty liver disease remains an active area of research, and ALA should not be considered a replacement for established lifestyle interventions.

What does the current evidence say about alpha lipoic acid for fatty liver?

Current evidence is promising but limited, with small trials showing modest reductions in liver enzymes and oxidative stress markers. No UK guideline recommends ALA for fatty liver disease.

The current evidence on alpha lipoic acid for fatty liver is promising but limited, and no UK regulatory body or clinical guideline currently recommends ALA as a treatment for NAFLD/MASLD or any other liver condition. Most of the available data come from small randomised controlled trials, animal studies, and observational research, which limits the strength of conclusions that can be drawn.

Several small human trials have examined ALA supplementation in people with NAFLD/MASLD or related metabolic conditions. Some studies have reported modest reductions in liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are markers of liver inflammation and cell damage. A number of trials have also observed improvements in insulin sensitivity and reductions in markers of oxidative stress following ALA supplementation. However, these studies have generally been short in duration, involved small participant numbers, and used varying doses and formulations, making direct comparison difficult. Most trials have assessed biochemical markers rather than histological endpoints such as steatosis grade, inflammation, or fibrosis, so the impact of ALA on the underlying liver tissue remains unclear.

A 2019 systematic review published in the journal Nutrients examined the effects of ALA on metabolic parameters and found some evidence of benefit on glycaemic control and lipid profiles, both of which are relevant to NAFLD/MASLD progression. However, the authors noted significant heterogeneity between studies and called for larger, well-designed trials before firm recommendations could be made.

NICE guidance on NAFLD (NG49) does not include ALA among its recommended interventions.^[1] The cornerstone of management remains lifestyle modification, including weight loss, dietary improvement, and increased physical activity. Some individuals explore supplementation alongside these measures, but this should always be discussed with a GP or specialist, particularly in the context of existing liver disease or concurrent medications.

Is alpha lipoic acid safe to take if you have liver problems?

ALA is generally well tolerated but people with liver problems should seek medical advice before use, as metabolism may be altered and interactions with prescribed medicines are possible.

Alpha lipoic acid is generally considered well tolerated at commonly used supplemental doses, but people with existing liver problems should seek medical advice before taking it. ALA is not a licensed medicine in the UK and is sold as a food supplement, meaning it is not subject to the same regulatory scrutiny as medicines authorised by the MHRA.^[11] This distinction matters when assessing safety, particularly for individuals with compromised liver function.

Reported side effects of ALA supplementation include:

• Gastrointestinal symptoms such as nausea, stomach discomfort, and diarrhoea, particularly at higher doses

• Skin reactions, including rash or itching in some individuals

• Hypoglycaemia, especially in people taking insulin or sulfonylureas, as ALA may enhance insulin sensitivity.^[5] People with diabetes should monitor their blood glucose more frequently when starting ALA and should not adjust their diabetes medicines without first speaking to a clinician

• Insulin autoimmune syndrome, a rare condition in which ALA may trigger the production of insulin antibodies, leading to unpredictable hypoglycaemia. This has been reported in case series and is more commonly described in people of certain genetic backgrounds

• Thiamine (vitamin B1) depletion with very high or prolonged doses. This is uncommon at standard supplemental amounts but may be of particular relevance in people with alcohol dependence or malnutrition, where thiamine status should be assessed separately

ALA is not recommended during pregnancy or breastfeeding, and its safety in people under 18 years of age has not been established.^[10] These groups should not take ALA unless specifically advised to do so by a clinician.

For people with significant liver impairment, the metabolism of ALA may be altered, and the risk of adverse effects could be higher. If you are taking prescribed medicines for liver disease, diabetes, or any other condition, speak to your GP before starting ALA, as interactions are possible.

Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Anyone experiencing new or worsening symptoms such as jaundice, significant abdominal pain, or unexplained fatigue should contact their GP promptly, or call NHS 111 for urgent advice.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
2. Global epidemiological patterns and disease burden of MASLD – 2023 multisociety Delphi consensus nomenclature.
3. Natural history of NASH and HCC.
4. Diagnostic performance of FIB-6 for identifying FibroScan-defined advanced fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
5. Molecular aspects of lipoic acid in the prevention of diabetes complications.
6. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways.
7. α-Lipoic Acid Alleviates Non-Alcoholic Fatty Liver Disease by Elevating Chaperone-Mediated Autophagy and Increasing β-Oxidation via AMPK-TFEB Axis.
8. The effects of alpha-lipoic acid supplementation on metabolic parameters (systematic review, Nutrients 2018).
9. Insulin Autoimmune Syndrome possibly caused by alpha-lipoic acid.
10. Safety of oral alpha-lipoic acid treatment in pregnant women.
11. Decide if your product is a medicine or a medical device.

Frequently Asked Questions